ASCO Offers Glimpse Of LAG-3 Inhibitors’ Potential Opportunities – And Limitations

PD-1-Naïve Patients More Likely To Derive Benefit

 
• By Alaric DeArment
  
3d illustration of T cells attacking a cancer cell
Several studies of LAG-3-targeting drugs combined with PD-1 and PD-L1 inhibitors are being presented at ASCO • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from ASCO

More from Conferences